Skip Nav Destination
Issues
15 April 2023
-
Cover Image
Cover Image
Immunofluorescence image of resected pancreatic ductal adenocarcinoma (PDAC) from a patient with locally advanced PDAC treated with total neoadjuvant therapy with losartan, FOLFIRINOX, and chemoradiation. Staining shows residual carcinoma (cytokeratin+, yellow), CD4+ T cells (white), and FOXP3+ cells (magenta). Nuclei are highlighted with DAPI (cyan). Immunosuppressive FOXP3+ cancer cells are increased in patients with a partial/poor pathological response. For details, see the article by Boucher and colleagues on page 1605 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Reviews
Perspectives
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric-Bernstam; James M. Ford; Peter J. O'Dwyer; Geoffrey I. Shapiro; Lisa M. McShane; Boris Freidlin; Roisin E. O'Cearbhaill; Suzanne George; Julia Glade-Bender; Gary H. Lyman; James V. Tricoli; David Patton; Stanley R. Hamilton; Robert J. Gray; Douglas S. Hawkins; Bhanumati Ramineni; Keith T. Flaherty; Petros Grivas; Timothy A. Yap; Jordan Berlin; James H. Doroshow; Lyndsay N. Harris; Jeffrey A. Moscow; on behalf of ComboMATCH study team
Research Briefs: Clinical Trial Brief Reports
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Arielle Elkrief; Alex Makhnin; Khadeja A. Moses; Linda S. Ahn; Isabel R. Preeshagul; Afsheen N. Iqbal; Sara A. Hayes; Andrew J. Plodkowski; Paul K. Paik; Marc Ladanyi; Mark G. Kris; Gregory J. Riely; Franziska Michor; Helena A. Yu
Clinical Trials: Targeted Therapy
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer
Sarah Halford; Gareth J. Veal; Stephen R. Wedge; Geoffrey S. Payne; Chris M. Bacon; Philip Sloan; Ilaria Dragoni; Kathrin Heinzmann; Sarah Potter; Becky M. Salisbury; Maxime Chénard-Poirier; Alastair Greystoke; Elizabeth C. Howell; William A. Innes; Karen Morris; Chris Plummer; Mihaela Rata; George Petrides; Hector C. Keun; Udai Banerji; Ruth Plummer
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Tingyu Wang; Xiuhua Sun; Lihua Qiu; Hang Su; Junning Cao; Zhiming Li; Yuqin Song; Li Zhang; Dengju Li; Huijing Wu; Wei Zhang; Junmin Li; Keshu Zhou; Hui Zhou; Yu Yang; Zhifeng Li; Hong Cen; Zhen Cai; Zhihui Zhang; Weijun Fu; Jie Jin; Fei Li; Weixin Wu; Xuekui Gu; Weiliang Zhu; Lihong Liu; Zengjun Li; Shuhua Yi; Hanying Bao; Zusheng Xu; Lugui Qiu
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Sarah Jenkins; Wei Zhang; Seth M. Steinberg; Darryl Nousome; Nicole Houston; Xiaolin Wu; Terri S. Armstrong; Eric Burton; Dee Dee Smart; Ritu Shah; Cody J. Peer; Brett Mozarsky; Oluwatobi Arisa; William D. Figg; Tito R. Mendoza; Elizabeth Vera; Priscilla Brastianos; Scott Carter; Mark R. Gilbert; Carey K. Anders; Roisín M. Connolly; Carol Tweed; Karen L. Smith; Imran Khan; Stanley Lipkowitz; Patricia S. Steeg; Alexandra S. Zimmer
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Kohei Shitara; Motohiro Hirao; Satoru Iwasa; Takashi Oshima; Yoshito Komatsu; Akihito Kawazoe; Yasuyoshi Sato; Takuya Hamakawa; Kan Yonemori; Nozomu Machida; Satoshi Yuki; Takuya Suzuki; Shiori Okumura; Takao Takase; Taro Semba; Bob Zimmermann; Angela Teng; Kensei Yamaguchi
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
Grazia Arpino; Juan de la Haba Rodríguez; Jean-Marc Ferrero; Sabino De Placido; C. Kent Osborne; Dirk Klingbiel; Valentine Revelant; Christine Wohlfarth; Raf Poppe; Mothaffar F. Rimawi; for the PERTAIN Study Group
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Amy S. Clark; Fangxin Hong; Richard S. Finn; Angela M. DeMichele; Edith P. Mitchell; James Zwiebel; Fernanda I. Arnaldez; Robert J. Gray; Victoria Wang; Lisa M. McShane; Larry V. Rubinstein; David Patton; P. Mickey Williams; Stanley R. Hamilton; Mehmet S. Copur; Samer S. Kasbari; Ravneet Thind; Barbara A. Conley; Carlos L. Arteaga; Peter J. O'Dwyer; Lyndsay N. Harris; Alice P. Chen; Keith T. Flaherty
Clinical Trials: Immunotherapy
Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
Wei Chen; Hui Shi; Zhuojun Liu; Fan Yang; Jia Liu; Leqiang Zhang; Yajin Wu; Yuanshi Xia; Yuxuan Ou; Ruiting Li; Ting Zhang; Jiecheng Zhang; Xiaoyan Ke; Kai Hu; Jian Yu
Precision Medicine and Imaging
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Niklas Klümper; Damian J. Ralser; Jörg Ellinger; Florian Roghmann; Julia Albrecht; Eduard Below; Abdullah Alajati; Danijel Sikic; Johannes Breyer; Christian Bolenz; Friedemann Zengerling; Philipp Erben; Kristina Schwamborn; Ralph M. Wirtz; Thomas Horn; Dora Nagy; Marieta Toma; Glen Kristiansen; Thomas Büttner; Oliver Hahn; Viktor Grünwald; Christopher Darr; Eva Erne; Steffen Rausch; Jens Bedke; Katrin Schlack; Mahmoud Abbas; Stefanie Zschäbitz; Constantin Schwab; Alexander Mustea; Patrick Adam; Andreas Manseck; Bernd Wullich; Manuel Ritter; Arndt Hartmann; Jürgen Gschwend; Wilko Weichert; Franziska Erlmeier; Michael Hölzel; Markus Eckstein
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
Akira Sugimoto; Shingo Matsumoto; Hibiki Udagawa; Ryo Itotani; Yuko Usui; Shigeki Umemura; Kazumi Nishino; Ichiro Nakachi; Shoichi Kuyama; Haruko Daga; Satoshi Hara; Shingo Miyamoto; Terufumi Kato; Jun Sakakibara-Konishi; Eriko Tabata; Taku Nakagawa; Tomoya Kawaguchi; Tetsuya Sakai; Yuji Shibata; Hiroki Izumi; Kaname Nosaki; Yoshitaka Zenke; Kiyotaka Yoh; Koichi Goto
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Austin R. Pantel; Sarah B. Gitto; Mehran Makvandi; Hyoung Kim; Sergey Medvedv; Joanna K. Weeks; Drew A. Torigian; Chia-Ju Hsieh; Benjamin Ferman; Nawar A. Latif; Janos L. Tanyi; Lainie P. Martin; Shannon M. Lanzo; Fang Liu; Quy Cao; Gordon B. Mills; Robert K. Doot; David A. Mankoff; Robert H. Mach; Lilie L. Lin; Fiona Simpkins
Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
Younes Belkouchi; Hugues Talbot; Nathalie Lassau; Littisha Lawrance; Siham Farhane; Rahma Feki-Mkaouar; Joya Hadchiti; Lama Dawi; Julien Vibert; Paul-Henry Cournède; Clara Cousteix; Camille Mazza; Michele Kind; Antoine Italiano; Aurelien Marabelle; Samy Ammari; Stephane Champiat
Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
Chaoyang Zhang; Fawaz N. Al-Shaheri; Mohamed Saiel Saeed Alhamdani; Andrea S. Bauer; Jörg D. Hoheisel; Miriam Schenk; Ulf Hinz; Philipp Goedecke; Karam Al-Halabi; Markus W. Büchler; Nathalia A. Giese; Thilo Hackert; Susanne Roth
Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report
Navin Pinto; Arlene Naranjo; Xiangming Ding; Fan F. Zhang; Emily Hibbitts; Rebekah Kennedy; Rachelle Tibbetts; Shannon Wong-Michalak; David W. Craig; Zarko Manojlovic; Michael D. Hogarty; Susan Kreissman; Rochelle Bagatell; Meredith S. Irwin; Julie R. Park; Shahab Asgharzadeh
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Ángel Guerrero-Zotano; Stefania Belli; Christoph Zielinski; Miguel Gil-Gil; Antonio Fernandez-Serra; Manuel Ruiz-Borrego; Eva Maria Ciruelos Gil; Javier Pascual; Montserrat Muñoz-Mateu; Begoña Bermejo; Mireia Margeli Vila; Antonio Antón; Laura Murillo; Bella Nissenbaum; Yuan Liu; Jesús Herranz; Daniel Fernández-García; Rosalía Caballero; José Antonio López-Guerrero; Roberto Bianco; Luigi Formisano; Nicholas Turner; Miguel Martín
Translational Cancer Mechanisms and Therapy
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Carsten Denkert; Chiara Lambertini; Peter A. Fasching; Katherine L. Pogue-Geile; Max S. Mano; Michael Untch; Norman Wolmark; Chiun-Sheng Huang; Sibylle Loibl; Eleftherios P. Mamounas; Charles E. Geyer, Jr; Peter C. Lucas; Thomas Boulet; Chunyan Song; Gail D. Lewis; Malgorzata Nowicka; Sanne de Haas; Mark Basik
Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Emil Christensen; Iver Nordentoft; Karin Birkenkamp-Demtröder; Sara K. Elbæk; Sia V. Lindskrog; Ann Taber; Tine G. Andreasen; Trine Strandgaard; Michael Knudsen; Philippe Lamy; Mads Agerbæk; Jørgen B. Jensen; Lars Dyrskjøt
MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Dana C. Borcherding; Neha V. Amin; Kevin He; Xiaochun Zhang; Yang Lyu; Carina Dehner; Himanshi Bhatia; Angad Gothra; Layla Daud; Peter Ruminski; Christine A. Pratilas; Kai Pollard; Taylor Sundby; Brigitte C. Widemann; Angela C. Hirbe
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer
Yves Boucher; Jessica M. Posada; Sonu Subudhi; Ashwin S. Kumar; Spencer R. Rosario; Liqun Gu; Heena Kumra; Mari Mino-Kenudson; Nilesh P. Talele; Dan G. Duda; Dai Fukumura; Jennifer Y. Wo; Jeffrey W. Clark; David P. Ryan; Carlos Fernandez-Del Castillo; Theodore S. Hong; Mikael J. Pittet; Rakesh K. Jain
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Laura Boucai; Mahesh Saqcena; Fengshen Kuo; Ravinder K. Grewal; Nicholas Socci; Jeffrey A. Knauf; Gnana P. Krishnamoorthy; Mabel Ryder; Alan L. Ho; Ronald A. Ghossein; Luc G.T. Morris; Venkatraman Seshan; James A. Fagin
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Gonzalo Rodriguez-Berriguete; Marco Ranzani; Remko Prevo; Rathi Puliyadi; Nicole Machado; Hannah R. Bolland; Val Millar; Daniel Ebner; Marie Boursier; Aurora Cerutti; Alessandro Cicconi; Alessandro Galbiati; Diego Grande; Vera Grinkevich; Jayesh B. Majithiya; Desiree Piscitello; Eeson Rajendra; Martin L. Stockley; Simon J. Boulton; Ester M. Hammond; Robert A. Heald; Graeme C.M. Smith; Helen M.R. Robinson; Geoff S. Higgins
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds